Core Viewpoint - The company is considering establishing a joint venture with Genetron Health in Singapore, with potential business development in Indonesia, Malaysia, and Singapore [1] Group 1: Joint Venture Details - The proposed joint venture will register a new entity in Indonesia focused on designing, constructing, and operating clinical molecular diagnostic laboratories centered on precision oncology [1] - The joint venture aims to provide advanced gene testing, including cancer screening, to assist doctors in early disease detection and tailor treatment plans for patients [1] Group 2: Product Offerings - Key products include early cancer screening (e.g., Genetron Health's innovative HCCscreen and HCCscan for hepatocellular carcinoma), comprehensive genomic analysis, minimal residual disease (MRD) monitoring, and non-invasive prenatal testing (NIPT) [2] - Initial operations will focus on laboratory-developed tests (LDT) and will gradually expand to local manufacturing and broader insurance coverage using Genetron Health's technology and regulatory framework [2] Group 3: Strategic Partnerships and Compliance - The joint venture is expected to establish clinical and business partnerships with renowned hospitals and medical institutions in Indonesia for sample collection, product validation, and early clinical applications [3] - A joint board and management team will be formed for strategic oversight, and the joint venture will handle all necessary regulatory filings with Indonesian authorities while adhering to local health regulations [3]
巨星医疗控股(02393.HK)拟与Genetron Health在新加坡成立合营企业 发展印尼、马来西亚及新加坡业务